Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 8/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30516108 | 1.00 | CETP (0.59) | CETPCHRM2CHRM1CHRM3DAO | |
| SCHEMBL4164702 | 0.93 | CETP (0.56) | CETPCHRM2CHRM1CHRM3DAO | |
| SCHEMBL30677435 | 0.85 | CHRM2 (0.55) | CETPCHRM2CHRM1CHRM3DAO | |
| SCHEMBL3119286 | 0.85 | CHRM2 (0.55) | CETPCHRM2CHRM1CHRM3DAO | |
| SCHEMBL5009648 | 0.84 | DAO (0.55) | CETPCHRM2CHRM1CHRM3DAO | |
| SCHEMBL3284271 | 0.84 | CETP (0.51) | CETP | |
| SCHEMBL178310 | 0.82 | CHRM2 (0.55) | CETPCHRM2CHRM1CHRM3DAO | |
| SCHEMBL19062249 | 0.82 | CETP (0.53) | CETPCHRM2CHRM1CHRM3DAO | |
| SCHEMBL80141 | 0.82 | CHRM2 (0.52) | CETPCHRM2CHRM1CHRM3DAO | |
| SCHEMBL2094315 | 0.81 | CETP (0.51) | CETPCHRM2CHRM1CHRM3DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 799 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114773330-B | Butylphthalide-oxa/thiadiazole compound and preparation method and application thereof | 贵州医科大学 | 2024-03-15 | — | — | CN | claimed |
| CN-114773330-A | Butylphthalide-oxa/thiadiazole compound and preparation method and application thereof | 贵州医科大学 | 2022-07-22 | — | — | CN | claimed |
| WO-2026099594-A1 | THERAPEUTIC BIFUNCTIONAL AGENTS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2026-05-15 | — | — | WO | disclosed |
| US-12570675-B2 | Boronic acid compounds | LG CHEM, LTD. (KR) | 2026-03-10 | — | — | US | disclosed |
| EP-4692085-A2 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| EP-4041388-B1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2025-09-23 | — | — | US | disclosed |
| US-20250282783-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-12410142-B2 | Substituted imidazole salt compounds, preparation method thereof, pharmaceutical composition thereof and application thereof | XIAMEN VIVOHEALTHS TECHNOLOGY CO., LTD. (CN) | 2025-09-09 | — | — | US | disclosed |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4561561-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | Septerna, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-5824687-A | BACTERICIDE, ANTIULCER AGENTS TREATING STOMACH OR INTESTINE CAUSED BY CAMPYLOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-10-20 | — | — | US | disclosed |
| WO-1997038665-A2 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-23 | — | — | WO | disclosed |
| US-4596880-A | Pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 1986-06-24 | — | — | US | disclosed |
| EP-0006978-B1 | BENZYL ESTERS WITH FLUORINATED ETHER AND/OR THIOETHER GROUPS, THEIR PREPARATIONS AND THEIR USE AS INSECTICIDES; INTERMEDIATE PRODUCTS AND THEIR PREPARATIONS | BAYER AG (DE) | 1986-01-29 | — | — | EP | disclosed |
| US-4438275-A | 2,2-DIFLUORO-BENZODIOXOLES | BAYER AKTIENGESELLSCHAFT (DE) | 1984-03-20 | — | — | US | disclosed |
| US-4411912-A | Insecticidal isovaleric acid esters | ZOECON CORPORATION (US) | 1983-10-25 | — | — | US | disclosed |
| US-4310540-A | PYRETHROID-LIKE COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1982-01-12 | — | — | US | disclosed |
| US-4243819-A | Substituted amino acids | ZOECON CORPORATION (US) | 1981-01-06 | — | — | US | disclosed |
| EP-0006978-A2 | Benzyl esters with fluorinated ether and/or thioether groups, their preparations and their use as insecticides; intermediate products and their preparations | BAYER AG (DE) | 1980-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | PSMB6, PSMB3, PSMB2 | CETP 1683/4885CHRM2 128/4885CHRM1 76/4885 |
| US-20250282783-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | USP28, USP25, USP24 | CETP 3173/4885CHRM2 4753/4885CHRM1 4554/4885 |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | CETP 1855/4885CHRM2 1412/4885CHRM1 1381/4885 |
| US-12410142-B2 | Substituted imidazole salt compounds, preparation method thereof, pharmaceutical composition thereof and application thereof | ALDOA, IDE, ACAT1 | CETP 111/4885CHRM2 2734/4885CHRM1 3651/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | CETP 3592/4885CHRM2 136/4885CHRM1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.